-
公开(公告)号：US20240173303A1
公开(公告)日：2024-05-30
申请号：US18213019
申请日：2023-06-22
发明人： Andrew P. Combs , Eddy W. Yue , Richard B. Sparks , Wenyu Zhu , Jiacheng Zhou , Qiyan Lin , Lingkai Weng , Tai-Yuen Yue , Pingli Liu
IPC分类号： A61K31/4245 , A61K39/395 , C07D271/08 , C07D413/04 , C07D413/12
CPC分类号： A61K31/4245 , A61K39/3955 , C07D271/08 , C07D413/04 , C07D413/12
摘要： The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
-
公开(公告)号：US11952367B2
公开(公告)日：2024-04-09
申请号：US17705079
申请日：2022-03-25
申请人： Incyte Corporation
发明人： Richard B. Sparks , Stacey Shepard , Andrew P. Combs , Andrew W. Buesking , Lixin Shao , Haisheng Wang , Nikoo Falahatpisheh
IPC分类号： C07D401/14 , C07D403/14 , C07D405/14 , C07D487/08 , C07D487/10 , C07D491/107
CPC分类号： C07D401/14 , C07D403/14 , C07D405/14 , C07D487/08 , C07D487/10 , C07D491/107
摘要： The present disclosure provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that modulate the activity of phosphoinositide 3-kinases-gamma (PI3Kγ) and are useful in the treatment of diseases related to the activity of PI3Kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
-
公开(公告)号：US11926630B2
公开(公告)日：2024-03-12
申请号：US17537674
申请日：2021-11-30
申请人： Incyte Corporation
发明人： Brent Douty , Andrew W. Buesking , David M. Burns , Andrew P. Combs , Nikoo Falahatpisheh , Ravi Kumar Jalluri , Daniel Levy , Padmaja Polam , Lixin Shao , Stacey Shepard , Artem Shvartsbart , Richard B. Sparks , Eddy W. Yue
IPC分类号： C07D487/04 , A61P35/00 , A61P25/28
CPC分类号： C07D487/04 , A61P25/28 , A61P35/00 , C07B2200/07 , C07B2200/13
摘要： This application relates to compounds of Formula (I):
or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.-
公开(公告)号：US11498926B2
公开(公告)日：2022-11-15
申请号：US17118891
申请日：2020-12-11
IPC分类号： C07D498/06 , C07D498/16 , C07D471/06 , A61P35/00 , C07D519/00
摘要： The present invention relates to tricyclic heterocycles of Formula (I): which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
-
公开(公告)号：US20210188872A1
公开(公告)日：2021-06-24
申请号：US17118891
申请日：2020-12-11
IPC分类号： C07D498/06 , C07D498/16 , C07D471/06 , A61P35/00 , C07D519/00
摘要： The present invention relates to tricyclic heterocycles of Formula (I): which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
-
公开(公告)号：US20200323858A1
公开(公告)日：2020-10-15
申请号：US16828315
申请日：2020-03-24
发明人： Yun-Long Li , Wenqing Yao , Andrew P. Combs , Eddy W. Yue , Song Mei , Joseph Glenn , Thomas P. Maduskuie, Jr. , Richard B. Sparks , Brent Douty , Chunhong He
IPC分类号： A61K31/519 , A61P29/00 , C07D471/04 , C07D487/04 , C07D519/00
摘要： The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
-
公开(公告)号：US10653677B2
公开(公告)日：2020-05-19
申请号：US16446253
申请日：2019-06-19
发明人： Andrew P. Combs , Eddy W. Yue , Richard B. Sparks , Wenyu Zhu
IPC分类号： A61K31/4245 , C07D271/08 , A61K39/395 , C07D413/12 , C07D413/04 , A61K39/00
摘要： The present invention is directed to 1,2,5-oxadiazole derivatives, and compositions of the same, which are inhibitors of indoleamine 2,3-dioxygenase and are useful in the treatment of cancer and other disorders, and to the processes and intermediates for making such 1,2,5-oxadiazole derivatives.
-
公开(公告)号：US10646492B2
公开(公告)日：2020-05-12
申请号：US16446098
申请日：2019-06-19
发明人： Yun-Long Li , Wenqing Yao , Andrew P. Combs , Song Mei , Joseph Glenn , Thomas P. Maduskuie, Jr. , Richard B. Sparks
IPC分类号： A61K31/519 , C07D471/04 , C07D487/04 , A61P29/00 , C07D519/00
摘要： The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
-
公开(公告)号：US10259818B2
公开(公告)日：2019-04-16
申请号：US15902742
申请日：2018-02-22
IPC分类号： A61K31/553 , C07D487/04 , C07C53/18 , A61K31/519
摘要： The present invention provides bicyclic azaheterocyclobenzylamines of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
-
公开(公告)号：US10227359B2
公开(公告)日：2019-03-12
申请号：US15802142
申请日：2017-11-02
申请人： Incyte Corporation
发明人： Andrew P. Combs , Richard B. Sparks
IPC分类号： C07D498/06
摘要： The present disclosure relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
-
-
-
-
-
-
-
-
-
搜索结果
98 条记录 (耗时 0.035 秒)
